Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) and Xencor (NASDAQ:XNCR – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.
Risk and Volatility
Centessa Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Earnings and Valuation
This table compares Centessa Pharmaceuticals and Xencor”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Centessa Pharmaceuticals | $6.85 million | 426.36 | -$235.76 million | ($1.79) | -12.18 |
| Xencor | $146.93 million | 4.17 | -$232.62 million | ($2.40) | -3.58 |
Xencor has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings for Centessa Pharmaceuticals and Xencor, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Centessa Pharmaceuticals | 0 | 0 | 11 | 1 | 3.08 |
| Xencor | 1 | 1 | 7 | 0 | 2.67 |
Centessa Pharmaceuticals presently has a consensus price target of $32.70, indicating a potential upside of 49.93%. Xencor has a consensus price target of $22.25, indicating a potential upside of 158.72%. Given Xencor’s higher probable upside, analysts clearly believe Xencor is more favorable than Centessa Pharmaceuticals.
Insider & Institutional Ownership
82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Centessa Pharmaceuticals and Xencor’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Centessa Pharmaceuticals | N/A | -40.39% | -29.87% |
| Xencor | -121.52% | -25.75% | -18.19% |
Summary
Centessa Pharmaceuticals beats Xencor on 9 of the 15 factors compared between the two stocks.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
About Xencor
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
